Progressive Vaccinia with Normal Antibodies
Authors: CORNELIUS J. O'CONNELL
Journal: Annals of Internal Medicine (1964)

Case Studies1 February 1964Progressive Vaccinia with Normal AntibodiesA Case Possibly Due to Deficient Cellular ImmunityCORNELIUS J. O'CONNELL, M.D., DAVID T. KARZON, M.D., ALMEN L. BARRON, PH.D., MARTIN E. PLAUT, M.D., VILAYAT M. ALI, M.D.CORNELIUS J. O'CONNELL, M.D., DAVID T. KARZON, M.D., ALMEN L. BARRON, PH.D., MARTIN E. PLAUT, M.D., VILAYAT M. ALI, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-60-2-282 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptOf the several complications attending vaccination against smallpox, the rarest and most grave is the development of progressive vaccinia. In this disorder the primary vaccination site fails to undergo its usual evolution which normally leads to regression in the second week. On the contrary, it spreads, becoming deep and necrotic. Metastatic lesions appear at distant cutaneous and visceral sites, and most cases terminate fatally. Progressive vaccinia, thus defined, is synonymous with "vaccinia gangrenosa" and "vaccinia necrotica" and must be differentiated from the more common condition, generalized vaccinia (Kaposi's varicelliform eruption) in which widespread lesions occur but then proceed to evolve...References1. LEWISJOHNSON HMFC: Fatal agammaglobulinemic progressive vaccinia. Arch. Derm. (Chicago) 75: 837, 1957. CrossrefGoogle Scholar2. SOMERS A: Vaccinia gangrenosa and agammaglobulinemia. Arch. Dis. Child. 32: 220, 1957. CrossrefMedlineGoogle Scholar3. CARSONDONNELL MJGN: Vaccinia gangrenosa: A case in a child with hypogammaglobulinemia. Calif. Med. 85: 335, 1956. MedlineGoogle Scholar4. KOZINNSIGELGARRIE PJMR: Progressive vaccinia associated with agammaglobulinemia and defects in immune mechanism. Pediatrics 16: 600, 1955. MedlineGoogle Scholar5. ERICHSONMCNAMARA RBMJ: Vaccinia gangrenosa: report of a case and review of the literature. Ann. Intern. Med. 55: 491, 1961. LinkGoogle Scholar6. OLANSKYSMITHHAUSEN-PREUSS SJGOL: Fatal vaccinia associated with cortisone therapy. JAMA 162: 887, 1956. CrossrefMedlineGoogle Scholar7. BARBEROGRAYSCOTTKEMPE GATCH: Vaccinia gangrenosa treated with hyperimmune vaccinia gamma globulin. Pediatrics 16: 609, 1955. MedlineGoogle Scholar8. BIGLERSLOTKOWSKI JE: Smallpox vaccination with prolonged vaccinia. Pediatrics 7: 24, 1951. MedlineGoogle Scholar9. KEMPEBENESON CHAS: Smallpox and vaccinia. Pediat. Clin. N. Amer. 2: 19, 1955. CrossrefGoogle Scholar10. BLAKE JC: Case of progressive vaccinia. Brit. Med. J. 2: 492, 1958. CrossrefMedlineGoogle Scholar11. HALLCUNLIFFEDUDGEON GFACJA: Prolonged generalized vaccinia. J. Path. Bact. 66: 25, 1953. CrossrefMedlineGoogle Scholar12. RAFFEL S: Immunity 2nd ed. Appleton-Century-Crofts, Inc., New York, pp. 462-470, 1961. Google Scholar13. SMADELSHEDLOVSKY JET: Antigens of vaccinia. Ann. NY Acad. Sci. 43: 35, 1942. CrossrefGoogle Scholar14. PARKER RF: Immunological studies of heat-stable substance isolated from tissues infected with vaccine virus. J. Exp. Med. 67: 361, 1938. CrossrefMedlineGoogle Scholar15. SMADELRIVERSHOAGLAND JETMCL: Nucleoprotein antigen of vaccine virus; new antigen from elementary bodies of vaccinia. Arch. Path. (Chicago) 34: 275, 1942. Google Scholar16. BURNETBOAKE FMWC: The relationship between the virus of infectious ectromelia in mice and vaccinia virus. J. Immun. 53: 1, 1946. MedlineGoogle Scholar17. FAIRBROTHER RW: The production of immunity to vaccinia virus by mixtures of immune serum and virus and the importance of phagocytosis in antivaccinial immunity. J. Path. Bact. 36: 55, 1933. CrossrefGoogle Scholar18. DOUGLASSMITH SRW: A study of vaccinial immunity in rabbits by means of in vitro methods. Brit. J. Exp. Path. 11: 96, 1930. Google Scholar19. DIENESNATERMAN LHC: The immunological response to vaccinia in guinea pigs. J. Infect. Dis. 60: 279, 1937. CrossrefGoogle Scholar20. GITLINGROSSJANEWAY DPCA: The gamma globulins and their clinical significance. New Eng. J. Med. 260: 21, 1959. CrossrefMedlineGoogle Scholar21. APT L: Yearbook of Pediatrics, 1953-1954 edition, Yearbook Publishers, Chicago, 1954, p. 67. Google Scholar22. DAVIDSONHAYHOE EFG: Prolonged generalized vaccinia complicating acute leukemia. Brit. Med. J. 2: 1298, 1962. CrossrefMedlineGoogle Scholar23. DALYJACKSON JJE: Vaccinia gangrenosa treated with N-methylisaton beta-thiosemicarbazone. Brit. Med. J. 2: 1300, 1962. CrossrefMedlineGoogle Scholar24. KEMPE CH: Studies on smallpox and complications of smallpox vaccination. Pediatrics 26: 176. MedlineGoogle Scholar25. CONNOLLYDICKFIELD JHGWCM: A fatal case of progressive vaccinia. Brit. Med. J. 1: 1315, 1962. CrossrefMedlineGoogle Scholar26. FRIEDMANBARONBUCKLERSTEINMULLER RMSCERI: The role of antibody, delayed hypersensitivity, and interferon production in recovery of guinea pigs from primary infection with vaccinia virus. J. Exp. Med. 116: 347, 1962. CrossrefMedlineGoogle Scholar27. KEMPE CH: in Diagnostic Procedures for Viral and Rickettsial Diseases: Variola and Vaccinia. (2nd ed.) New York: American Public Health Association, 1956. Google Scholar28. CUTCHINSWAVENJONES EJWP: The antibody response to smallpox vaccination as measured by a tissue culture plaque method. J. Immun. 85: 275, 1960. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: CORNELIUS J. O'CONNELL, M.D.; DAVID T. KARZON, M.D.; ALMEN L. BARRON, PH.D.; MARTIN E. PLAUT, M.D.; VILAYAT M. ALI, M.D.Affiliations: Buffalo, New YorkFrom the Departments of Medicine, Pediatrics, and Bacteriology and Immunology, School of Medicine, State University of New York at Buffalo, New York.This study was supported in part by a Public Health Service Research Career Program Award (AI-K6-1136) from the National Institute of Allergy and Infectious Diseases, United States Public Health Service, Bethesda, Maryland.Requests for reprints should be addressed to Cornelius O'Connell, M.D., Department of Medicine, State University of New York, Buffalo School of Medicine, 100 High Street, Buffalo 3, New York. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byHumoral Immunity to Primary Smallpox Vaccination: Impact of Childhood versus Adult Immunization on Vaccinia Vector Vaccine Development in Military PopulationsEliciting Epitope-Specific CD8+ T Cell Response by Immunization with Microbial Protein Antigens Formulated with α-Galactosylceramide: Theory, Practice, and ProtocolsDiscovering naturally processed antigenic determinants that confer protective T cell immunityCritical Role of Perforin-dependent CD8+ T Cell Immunity for Rapid Protective Vaccination in a Murine Model for Human SmallpoxVaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumorsThird-generation smallpox vaccines: challenges in the absence of clinical smallpoxDiverse recognition of conserved orthopoxvirus CD8+ T cell epitopes in vaccinated rhesus macaquesDiminished Intracellular Invariant Chain Expression after Vaccinia Virus InfectionDNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challengeProtection against Vaccinia Virus Challenge by CD8 Memory T Cells Resolved by Molecular MimicryÉvaluation des réponses immunitaires résiduelles chez des sujets volontaires avant et après revaccination contre la varioleDifferential Regulation of Granzyme and Perforin in Effector and Memory T Cells following Smallpox ImmunizationDetermination of immunity to vaccinia virus by using diluted inactivated vaccinia vaccine solution for skin testingSmallpox vaccination recommendations for contacts of pediatric cancer patientsEvolution of Vaccinia Virus-Specific CD8 + Cytotoxic T-Lymphocyte Responses in Primary Vaccinees and RevaccineesLong-Lived Poxvirus Immunity, Robust CD4 Help, and Better Persistence of CD4 than CD8 T CellsRapid Detection and Differentiation of Human Pathogenic Orthopox Viruses by a Fluorescence Resonance Energy Transfer Real-Time PCR AssayAge Distribution for T Cell Reactivity to Vaccinia Virus in a Healthy PopulationSmallpox Vaccination in 2003: Key Information for CliniciansProgressive VacciniaFour-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primatesHow Contagious Is Vaccinia?Dose-Related Effects of Smallpox VaccineClinical Responses to Undiluted and Diluted Smallpox VaccineUse of Licensed Vaccines for Active Immunization of the Immunocompromised HostMultigenic evasion of inflammation by poxvirusesVaccinia virus-specific CD8+ cytotoxic T lymphocytes in humansVaccinia virus-specific human CD4+ cytotoxic T-lymphocyte clonesPoxvirus pathogenesisViral Infections in Immunocompromised PatientsSymposium on Host-Parasite Interactions: Umeå, Sweden, June 6–8, 1979Transfer Factor and Its Clinical ApplicationTransfer factorDouble-blind trial of the use of transfer factor in the treatment of Crohn's disease.Progressive vaccinia: Immunological aspects and transfer factor therapyImpaired defense against vaccinia in a child with T-lymphocyte deficiency associated with inosine phosphorylase defectTransfer factor treatment of chronic mucocutaneous candidiasis: Requirement for donor reactivity to Candida antigenTransfer factor: A potential agent for immunotherapy of cancerUndernutrition and Immunity: Smallpox Vaccination in Chronically Starved, Undernourished Subjects and Its Immunologic EvaluationImmunotherapy of viral infections with transfer factorTransfer Factor: A Potential Agent for Cancer TherapyHUMORAL IMMUNE RESPONSE TO VIRAL INFECTIONSTransfer Factor and Cellular Immunity to Viral InfectionInteractions of Antibodies, Complement Components and Various Cell Types in Immunity Against Viruses and Pyogenic BacteriaTransfer factor therapy in a case of complex immunodeficiencyPocken(Pox)- und verwandte VirenSelective Immunotherapy with Transfer FactorCell-Mediated ImmunityConsequences of Smallpox Vaccination in Leprosy PatientsImmunologic and clinical improvement of progressive coccidioidomycosis following administration of transfer factorResponse of Specific Skin Hypersensitivity and Haemagglutination Inhibiting Antibody after Smallpox Vaccination in Human Newborns and AdultsStudies of the epstein-barr virus-host relationship: Autochthonous and allogeneic lymphocyte stimulation by lymphoblast cell lines in mixed cell cultureParticipation of Lymphocytes in Viral InfectionsVaccinia necrosum and its relationship to impaired immunologic responsivenessTransfer of Immune ResponsivenessNecropsy findings in a case of progressive vacciniaImmune responses in persistent virus infectionsNEW APPROACH TO IMMUNOTHERAPY OF MELANOMAAN AUTOPSY CASE OF PROGRESSIVE VACCINIA ASSOCIATED WITH NORMAL IMMUNOGLOBULIN LEVELSTransfer Factor and Cellular Immune Deficiency DiseaseImmunoprophylaxis of viral infections in childhoodThe Role of Immunoglobulins in the Mechanism of Mucosal Immunity to Virus InfectionProgressive vaccinia complicating lymphosarcomaOrthopoxvirus vaccines and vaccinationTransfer FactorVACCINIA GANGRENOSA WITH CIRCULATING VACCINIAL ANTIBODIES AND BENIGN INDOLENT VACCINIAL ULCERATION: CASE REPORTS AND DISCUSSIONCongenital Lipomatosis of the PancreasPox-Virus-KrankheitenPox-Virus-KrankheitenPathogenesis of rashes in virus diseasesVaccinia Gangrenosa with Normal Humoral Antibodies A Case Possibly Due to Deficient Cellular Immunity Treated with N-Methylisatin β-Thiosemicarbazone (Compound 33T57, Marboran)Cardiac Complications of Progressive Generalized VacciniaCurrent Status of Live Attenuated Virus VaccinesACTION OF ENDOGENOUS INTERFERON AGAINST VACCINIA INFECTION IN CHILDRENAcute Monarticular Arthritis After Vaccination Report of a Case with Isolation of Vaccinia Virus from Synovial FluidHOWARD M. SILBY, M.D., ROGER FARBER, M.D., CORNELIUS J. O'CONNELL, M.D., JULIAN ASCHER, M.D., EDWARD J. MARINE, M.D. 1 February 1964Volume 60, Issue 2_Part_1Page: 282-289KeywordsBacteriologyCareers in researchHealth services researchImmunologyInfectious diseasesInterferonsLesionsMedical servicesPediatricsSerum proteins ePublished: 1 December 2008 Issue Published: 1 February 1964 PDF downloadLoading ...